Physician profile
Christopher Kolasa
NPI 1073680062
$792.80
in general payments reported to CMS, 2019-2025
16 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.51 · 2022: $125 · 2024: $17.46 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.40 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $187.12 | 2021-2025 | Jynarque, Voyxact |
| Bard Peripheral Vascular, INC. | $125.00 | 2022 | |
| Calliditas Therapeutics US INC. | $77.47 | 2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $66.28 | 2025 | |
| Xeris Pharmaceuticals, INC. | $48.86 | 2025 | Keveyis |
| Novartis Pharmaceuticals Corporation | $45.22 | 2025 | |
| Travere Therapeutics, INC. | $36.31 | 2025 | Filspari |
| Ardelyx, INC. | $31.32 | 2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $26.11 | 2025 | Rayaldee |
| Novo Nordisk INC | $25.33 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.22 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $24.34 | 2025 | Lupkynis |
| Ascendis Pharma Endocrinology INC | $20.08 | 2025 | Yorvipath |
| Mallinckrodt Hospital Products INC. | $19.92 | 2025 | Acthar |
| Fresenius USA Marketing, INC. | $17.46 | 2024 | Velphoro |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.76 | 2025 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kolasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.